These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. G protein-coupled receptor heteromer identification technology: identification and profiling of GPCR heteromers. Mustafa S; Pfleger KD J Lab Autom; 2011 Aug; 16(4):285-91. PubMed ID: 21764024 [TBL] [Abstract][Full Text] [Related]
8. Allosteric modulation of G protein-coupled receptors. May LT; Avlani VA; Sexton PM; Christopoulos A Curr Pharm Des; 2004; 10(17):2003-13. PubMed ID: 15279541 [TBL] [Abstract][Full Text] [Related]
9. Shaky ground - The nature of metastable GPCR signalling complexes. Sleno R; Hébert TE Neuropharmacology; 2019 Jul; 152():4-14. PubMed ID: 30659839 [TBL] [Abstract][Full Text] [Related]
10. GPCR heteromers: An overview of their classification, function and physiological relevance. Dale NC; Johnstone EKM; Pfleger KDG Front Endocrinol (Lausanne); 2022; 13():931573. PubMed ID: 36111299 [TBL] [Abstract][Full Text] [Related]
11. G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter. Franco R Br J Pharmacol; 2009 Sep; 158(1):23-31. PubMed ID: 19422387 [TBL] [Abstract][Full Text] [Related]
12. G Protein-Coupled Receptor Heteromers. Gomes I; Ayoub MA; Fujita W; Jaeger WC; Pfleger KD; Devi LA Annu Rev Pharmacol Toxicol; 2016; 56():403-25. PubMed ID: 26514203 [TBL] [Abstract][Full Text] [Related]
13. Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development. Hurevich M; Talhami A; Shalev DE; Gilon C Curr Top Med Chem; 2014; 14(15):1842-63. PubMed ID: 25175995 [TBL] [Abstract][Full Text] [Related]
14. Emerging paradigms in GPCR allostery: implications for drug discovery. Wootten D; Christopoulos A; Sexton PM Nat Rev Drug Discov; 2013 Aug; 12(8):630-44. PubMed ID: 23903222 [TBL] [Abstract][Full Text] [Related]
15. Understanding the role of heteroreceptor complexes in the central nervous system. Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022 [TBL] [Abstract][Full Text] [Related]
16. Moonlighting characteristics of G protein-coupled receptors: focus on receptor heteromers and relevance for neurodegeneration. Borroto-Escuela DO; Tarakanov AO; Guidolin D; Ciruela F; Agnati LF; Fuxe K IUBMB Life; 2011 Jul; 63(7):463-72. PubMed ID: 21698749 [TBL] [Abstract][Full Text] [Related]
17. The role of GPCR dimerisation/oligomerisation in receptor signalling. Milligan G; Canals M; Pediani JD; Ellis J; Lopez-Gimenez JF Ernst Schering Found Symp Proc; 2006; (2):145-61. PubMed ID: 17703581 [TBL] [Abstract][Full Text] [Related]
18. When simple agonism is not enough: emerging modalities of GPCR ligands. Smith NJ; Bennett KA; Milligan G Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693 [TBL] [Abstract][Full Text] [Related]
19. Structural Characterization of Receptor-Receptor Interactions in the Allosteric Modulation of G Protein-Coupled Receptor (GPCR) Dimers. Lazim R; Suh D; Lee JW; Vu TNL; Yoon S; Choi S Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33810175 [TBL] [Abstract][Full Text] [Related]
20. Unmasking allosteric-binding sites: novel targets for GPCR drug discovery. Casadó-Anguera V; Casadó V Expert Opin Drug Discov; 2022 Aug; 17(8):897-923. PubMed ID: 35649692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]